Method, composition and device for sampling natriuretic peptides in a biological fluid
Disclosed is a composition that synergistically prevents proteolysis or modification of peptides in sampled biological fluids using sulfonyl fluoride family protease inhibitors at high concentrations combined with at least one additional protease inhibitor of a different type, preferably a broad spectrum protease inhibitor, and a chelator. A preferred embodiment uses AEBSF at 10 mM, Benzamidine at 20 mM and EDTA as the chelator. The disclosed composition may be combined with other protease inhibitors to further modulate its specificity, for instance to additionally target acidic proteases. Additional protease inhibitors, reducing agents, stabilizers and buffering agents may be combined with the disclosed compositions in devices for sampling or testing biological fluids for levels of peptides of interest, or methods therefore. The disclosed devices, compositions and methods are of particular use in sampling and testing for the level of natriuretic peptides.
1. A composition comprising a mixture of:
(a) a first protease inhibitor selected from the group consisting of leupeptin and benzamidine;
(b) a second protease inhibitor that is 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF), wherein the second protease inhibitor does not inhibit formation of protein adducts in the absence of the first protease inhibitor; and
(c) a natriuretic peptide;
wherein an effective amount of the first protease inhibitor and the second protease inhibitor is a concentration effective to inhibit proteolysis of the natriuretic peptide while not inducing formation of adducts of the natriuretic peptide when combined, and
wherein the effective amounts comprise:
(i) about 20 mM benzamidine and about 10 mM AEBSF, or
(ii) about 2.5 mM leupeptin and about 2.5 mM AEBSF.
2. The composition according to claim 1 , wherein the natriuretic peptide is ANP, BNP, CNP, or DNP.
3. The composition according to claim 1 , wherein the natriuretic peptide is a synthetic natriuretic peptide.
4. The composition according to claim 2 , wherein the natriuretic peptide is a pro-peptide of ANP, BNP, CNP, or DNP.
5. The composition according to claim 2 , wherein the natriuretic peptide is a prepro-peptide of ANP, BNP, CNP, or DNP.
6. The composition according to claim 1 , wherein the composition is stable for at least one of (i) two hours at room temperature, and (ii) at least six months at seventy degrees centigrade below zero.
7. The composition according to claim 1 , wherein the natriuretic peptide comprises a biological fluid containing the natriuretic peptide.
8. The composition according to claim 7 , wherein the biological fluid is blood, sweat, blister fluid, lung fluid, saliva, lacrimal gland secretion, cerebrospinal fluid, seminal fluid, lymph, or urine.
9. The composition according to claim 8 , wherein the biological fluid is blood or urine.
10. The composition according to claim 1 , further comprising a chelator.
11. The composition according to claim 10 , wherein the chelator is ethylenediaminetetraacetic acid.
12. The composition according to claim 10 , wherein the ethylenediaminetetraacetic acid is present in the composition at a concentration of at least about 1 mM.
13. A composition comprising a mixture of:
(a) about 20 mM benzamidine;
(b) about 10 mM AEBSF; and
(c) a natriuretic peptide.
14. The composition according to claim 13 , wherein the natriuretic peptide is ANP, BNP, CNP, or DNP, or a pro-peptide or a prepro-peptide thereof.
15. The composition according to claim 13 , further comprising a chelator.
16. The composition according to claim 15 , wherein the chelator is ethylenediaminetetraacetic acid.
17. A composition comprising a mixture of:
(a) about 2.5 mM leupeptin;
(b) about 2.5 mM AEBSF; and
(c) a natriuretic peptide.
18. The composition according to claim 17 , wherein the natriuretic peptide is ANP, BNP, CNP, or DNP, or a pro-peptide or a prepro-peptide thereof.
19. The composition according to claim 17 , further comprising a chelator.
20. The composition according to claim 19 , wherein the chelator is ethylenediaminetetraacetic acid.